# CheckMate 915 (NCT03068455)

> An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03068455
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Melanoma
- Interventions: nivolumab; ipilimumab
- Enrollment: 1844
- Primary outcome: Recurrence-free Survival (RFS) - All Randomized Participants
- Primary outcome: Recurrence-free Survival (RFS) - All Randomized Participants With PD-L1 Expression Level < 1%

## Commentary we found

- Podcasts: 11
- YouTube: 3
- X threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=checkmate-915-nct03068455

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03068455", "email": "<work email>"}; the inbox owner confirms by the emailed link.